Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4389099 | 0.90 | CRBN (0.57) | CRBNDDB1GRIN2B | |
| SCHEMBL4389196 | 0.81 | CRBN (0.60) | CRBNDDB1 | |
| SCHEMBL19370861 | 0.81 | CRBN (0.60) | CRBNDDB1 | |
| SCHEMBL4396934 | 0.81 | CRBN (0.60) | CRBNDDB1 | |
| SCHEMBL20812785 | 0.78 | EPHX2 (0.47) | CRBNDDB1 | |
| SCHEMBL6700373 | 0.77 | CRBN (0.64) | CRBNDDB1 | |
| SCHEMBL27848317 | 0.77 | CRBN (0.46) | CRBNDDB1 | |
| SCHEMBL25834149 | 0.77 | GRIN2B (0.46) | CRBNDDB1GRIN2BSIGMAR1GRIN1 | |
| SCHEMBL19359349 | 0.75 | CRBN (0.60) | CRBNDDB1 | |
| SCHEMBL29922912 | 0.75 | CRBN (0.60) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1252144-B1 | SUBSTITUTED GLUTARIMIDES AND USE THEREOF IL-12 PRODUCTION INHIBITORS | GRUENENTHAL GMBH (DE) | 2009-12-09 | — | — | EP | disclosed |
| US-20040048859-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GRUENENTHAL GMBH (DE) | 2004-03-11 | — | — | US | disclosed |
| US-6656937-B2 | Immunology moderators; interleukin antagonist; anticancer agents | GRUENENTHAL, GMBH (DE) | 2003-12-02 | — | — | US | disclosed |
| US-20030064987-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GRUENENTHAL GMBH | 2003-04-03 | — | — | US | disclosed |
| EP-1252144-A1 | SUBSTITUTED GLUTARIMIDES AND USE THEREOF IL-12 PRODUCTION INHIBITORS | Grünenthal GmbH (DE) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001053261-A1 | SUBSTITUTED GLUTARIMIDES AND USE THEREOF IL-12 PRODUCTION INHIBITORS | Grünenthal GmbH (DE) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048859-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GCDH, IL4I1, IL2 | CRBN 949/4885DDB1 2435/4885GRIN2B 506/4885 |
| US-20030064987-A1 | Substituted glutarimides and their use as inhibitors of IL-12 production | GCDH, IL4I1, IL2 | CRBN 949/4885DDB1 2435/4885GRIN2B 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.